TIDMAGL
RNS Number : 5373E
Angle PLC
07 July 2021
For immediate release 7 July 2021
ANGLE plc
("ANGLE" or the "Company")
Director/PDMR Shareholding
Exercise of Options
and Total Voting Rights
ANGLE plc (AIM: AGL OTCQX: ANPCY), a world-leading liquid biopsy
company, announces that it has agreed to allot 1,023,826 new
ordinary shares of 10 pence each in the capital of the Company
("Ordinary Shares"). This is following the exercise of share
options by Andrew Newland, Chief Executive of the Company, at
exercise prices of GBP0.2575 and GBP0.10 per Ordinary Share. Almost
all of the exercised share options pursuant to this transaction
were due to expire in August 2021. The new Ordinary Shares rank
pari passu with the existing Ordinary Shares in the Company.
Following the above exercise, Mr. Newland has today sold all
1,023,826 Ordinary Shares at a price of 125 pence per Ordinary
Share, for personal financial and estate planning purposes.
Following the above transactions, Mr. Newland's holdings in the
Company remain unchanged at 7,054,686 Ordinary Shares, representing
approximately 3.0 per cent. of the Company's issued share capital.
Mr Newland also holds share options over an additional 3,000,000
Ordinary Shares, and Long-Term Incentive Plan Options up to a
maximum of 5,400,000 additional Ordinary Shares, depending on
future performance conditions.
Application will be made to the London Stock Exchange for the
1,023,826 new Ordinary Shares to be admitted to trading on AIM
("Admission") and it is expected that Admission will become
effective and trading will commence at 8.00 a.m. on 14 July
2021.
Following Admission, the total number of Ordinary Shares in
issue will be 234,181,384 and the total number of voting rights
will therefore be 234,181,384. This figure may be used by
shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in, the share capital of the Company
under the FCA's Disclosure Guidance and Transparency Rules.
Contacts:
ANGLE plc +44 (0) 1483 343434
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
Andrew Holder, Head of Investor Relations
finnCap Ltd (NOMAD and Joint Broker)
Corporate Finance - Carl Holmes, Simon Hicks, Teddy Whiley
ECM - Alice Lane, Sunila de Silva +44 (0)20 7220 0500
WG Partners (Joint Broker)
Nigel Barnes, Nigel Birks +44 (0) 203 705 9330
FTI Consulting
Simon Conway, Ciara Martin +44 (0) 203 727 1000
Matthew Ventimiglia (US) +1 (212) 850 5624
For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a world leading liquid biopsy company with
sample-to-answer solutions. ANGLE's proven patent protected
platforms include a circulating tumor cell (CTC) harvesting
technology and a downstream analysis system for cost effective,
highly multiplexed analysis of nucleic acids and proteins.
ANGLE's cell separation technology is called the Parsortix (R)
system, and it enables a liquid biopsy (a simple blood test) to be
used to provide the cells of interest to the user in a format
suitable for multiple types of downstream analyses. The system is
based on a microfluidic device that captures cells based on a
combination of their size and compressibility. The system is
epitope independent and can capture all types of CTCs as well as
CTC clusters in a viable form (alive). CTCs enable the complete
picture of a cancer to be seen; as being an intact cell they allow
DNA, RNA and protein analysis and may provide comparable analysis
to a tissue biopsy. Because CTC analysis is a non-invasive process,
unlike tissue biopsy, it can be repeated as often as needed. This
is important because cancer develops and changes over time and
there is a clear medical need for up-to-date information on the
status of a patient's tumor. In addition, the live CTCs harvested
by the Parsortix system can be cultured, which offers the potential
for testing tumor response to drugs outside the patient.
The Parsortix technology is the subject of 26 granted patents in
Europe, the United States, China, Australia, Canada, India, Japan
and Mexico with three extensive families of patents are being
progressed worldwide.
The Parsortix system has a CE Mark in Europe for the indicated
use and, in the United States, a De Novo Submission has been made
to FDA for the Parsortix (R) PC1 system seeking FDA clearance with
Class II Classification for use with metastatic breast cancer
patients. FDA clearance is seen as the global standard. ANGLE is
seeking to be the first ever FDA cleared system for harvesting CTCs
for subsequent analysis.
ANGLE has also completed two separate 200 subject clinical
studies under a program designed to develop an ovarian cancer
pelvic mass triage test, with the results showing best in class
accuracy (AUC-ROC) of 95.1%. The pelvic mass triage assay has
undergone further refinement and optimisation and a 200 patient
clinical verification study has now completed enrolment.
ANGLE's technology for the multiplex evaluation of proteins and
nucleic acids of all types is called the HyCEAD (TM) platform and
is based on a patented flow through array technology. It provides
for low cost, highly multiplexed, rapid and sensitive capture of
targets from a wide variety of sample types. A proprietary
chemistry approach (the HyCEAD method) allows for the capture and
amplification of over 100 biomarkers simultaneously in a single
reaction. The HyCEAD system is extremely sensitive and is ideal for
measuring gene expression and other markers directly from Parsortix
harvests and was used in the ovarian cancer pelvic mass triage test
to achieve best in class accuracy (AUC-ROC) of 95.1%.
ANGLE's proprietary technologies can be combined to provide
automated, sample-to-answer results in both centralised laboratory
and point-of-use cartridge formats.
ANGLE has established formal collaborations with world-class
cancer centres and major corporates such as Abbott, Philips and
QIAGEN, and works closely with leading CTC translational research
customers. These Key Opinion Leaders (KOLs) are working to identify
applications with medical utility (clear benefit to patients), and
to secure clinical data that demonstrates that utility in patient
studies. The body of evidence as to the benefits of the Parsortix
system is growing rapidly from our own clinical studies in
metastatic breast cancer and ovarian cancer and also from KOLs with
45 peer-reviewed publications and numerous publicly available
posters, available on our website.
ANGLE's has established clinical services laboratories in the UK
and USA to accelerate commercialisation of the Parsortix system and
act as demonstrators to support product development. The
laboratories offer services to pharmaceutical and biotech customers
for use of Parsortix in cancer drug trials and, once the
laboratories are accredited and tests validated, will provide
Laboratory Developed Tests (LDTs) for patient management.
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
--- ----------------------------------------------------------------------------------------
a. Name Andrew Newland
------------------------------------------------------------
2 Reason for notification
-------------------------- ------------------------------------------------------------
a. Position/Status Chief Executive
-------------------------- ------------------------------------------------------------
b. Initial notification/ Initial Notification
Amendment
-------------------------- ------------------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------------------------
a. Name ANGLE Plc
--------------------------
b. LEI 213800BY11K6W3NMS374
-------------------------- ------------------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
--- ----------------------------------------------------------------------------------------
a. Description of Ordinary Shares of 10 pence each
the financial
instrument, type ISIN: GB0034330679
of instrument
Identification
Code
-------------------------- ------------------------------------------------------------
b. Nature of the Acquisition of Ordinary Shares following the
transaction Exercise of Share Options and Sale of Ordinary
Shares
-------------------------- ------------------------------------------------------------
c. Price(s) and volume(s) Price(s) Volume(s)
-------------------------- --------------
GBP0.2575 950,000 Purchase
-------------- ------------
GBP0.10 73,826 Purchase
-------------- ------------
GBP1.25 1,023,826 Sale
-------------- ------------
d. Aggregated information
Aggregated Purchase 1,023,826
Volume GBP0.2461
Aggregated Purchase
Price 1,023,826
Aggregated Sale GBP1.25
Volume
Aggregated Sale
Price
-------------------------- ------------------------------------------------------------
e. Date of the transaction 7 July 2021
-------------------------- ------------------------------------------------------------
f. Place of the transaction London Stock Exchange
-------------------------- ------------------------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHDDLFBFDLLBBK
(END) Dow Jones Newswires
July 07, 2021 13:34 ET (17:34 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2023 to Apr 2024
